跳转至内容
Merck

N3538

Sigma-Aldrich

那格列奈

≥98% (HPLC), solid

别名:

Fastic, N-[(trans-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine, Starlix, Starsis

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H27NO3
分子量:
317.42
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

solid

顏色

white to off-white

溶解度

DMSO: >5 mg/mL
H2O: insoluble

起源

Novartis

儲存溫度

room temp

SMILES 字串

CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(O)=O

InChI

1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1

InChI 密鑰

OELFLUMRDSZNSF-BRWVUGGUSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin.
Nateglinide is a short-acting insulin secretagogue useful in treating type 2 diabetes. It is an insulinotropic agent effective for postprandial hyperglycemia. Nateglinide restores prandial insulin levels in a glucose-dependent manner.

特點和優勢

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Julia Kreis et al.
Health policy (Amsterdam, Netherlands), 104(1), 27-31 (2011-12-06)
In Germany, coverage decisions in the statutory health insurance (SHI) system are based on the principles of evidence-based medicine. Recently, an evidence assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) of the oral antidiabetics of the
Julio Rosenstock et al.
Diabetes care, 27(6), 1265-1270 (2004-05-27)
A randomized, parallel-group, open-label, multicenter 16-week clinical trial compared efficacy and safety of repaglinide monotherapy and nateglinide monotherapy in type 2 diabetic patients previously treated with diet and exercise. Enrolled patients (n = 150) had received treatment with diet and
Toshiyuki Takanohashi et al.
European journal of drug metabolism and pharmacokinetics, 37(1), 9-15 (2011-10-21)
Nateglinide and mitiglinide are immediate short-acting insulinotropic agents. Both are administered preprandially to control postprandial hyperglycemia. Glinide drugs are characterized by immediate onset as well as rapid disappearance of effect as compared with sulfonylurea drugs. We examined the rapidity of
[Glinides].
Tomoya Mita et al.
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 3, 608-613 (2012-07-10)
A S Abdelmoneim et al.
Diabetes, obesity & metabolism, 14(2), 130-138 (2011-09-20)
Insulin secretagogues promote insulin release by binding to sulfonylurea receptors on pancreatic β-cells (SUR1). However, these drugs also bind to receptor isoforms on cardiac myocytes (SUR2A) and vascular smooth muscle (SUR2B). Binding to SUR2A/SUR2B may inhibit ischaemic preconditioning, an endogenous

商品

我们可提供多种与钙通道相关的产品以满足您的各类研究需求。

Sigma-Aldrich offers many products related to potassium channels for your research needs.

Glucose metabolism is regulated by the opposing actions of insulin and glucagon. Insulin is released from pancreatic ß cells in response to high blood glucose levels and regulates glucose metabolism through its actions on muscle, liver, and adipose tissue.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门